Numerate, a San Bruno, Calif.-based biotech company that streamlines pharmaceutical production pipelines and intellectual property protections, brought in $5.5. million in a second round of funding, according to peHUB. Called the Drug Engineering Process, its system helps research teams set and methodically achieve milestones across different areas, the company says. In its two case studies, it refined therapies for diabetes and HIV.
The funds came from Foundation Capital and Lanza TechVentures. Numerate has bagged $4 million to date.